Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: a prospective multicountry trial of a fully percutaneous transseptal mitral valve replacement (TMVR) system for patients unsuitable for surgery or TEER, an AI-driven pipeline that reconstructs right ventricular pressure–volume indices from routine catheterization inputs and predicts outcomes in pulmonary hypertension, and a long-term meta-analysis comparing durability of balloon-expandable vs self-expanding TAVR valves.
Summary
Three impactful cardiology studies stood out today: a prospective multicountry trial of a fully percutaneous transseptal mitral valve replacement (TMVR) system for patients unsuitable for surgery or TEER, an AI-driven pipeline that reconstructs right ventricular pressure–volume indices from routine catheterization inputs and predicts outcomes in pulmonary hypertension, and a long-term meta-analysis comparing durability of balloon-expandable vs self-expanding TAVR valves.
Research Themes
- Transcatheter structural heart interventions
- AI-enabled hemodynamic phenotyping
- Long-term durability of TAVR bioprostheses
Selected Articles
1. Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial.
In 299 high-risk patients unsuitable for surgery or TEER, percutaneous transseptal TMVR with SAPIEN M3 achieved a 1-year composite rate of death or HF rehospitalization of 25.2% (95% CI 20.6–30.6), significantly below the prespecified 45% performance goal. There were no intraprocedural deaths, no hemodynamically significant LVOT obstruction, and no conversions to surgery; median follow-up was 1.4 years.
Impact: This pivotal trial demonstrates feasibility, safety, and clinically meaningful benefit of a fully percutaneous TMVR option for a population with limited alternatives, potentially redefining treatment pathways for inoperable or non-TEER-suitable MR.
Clinical Implications: Percutaneous transseptal TMVR may be considered for symptomatic MR patients unsuitable for surgery or TEER, with low early complication rates. Programs should develop imaging-led patient selection and structured follow-up, while longer-term durability data are accrued.
Key Findings
- Primary 1-year composite (all-cause death or HF rehospitalization) was 25.2% (95% CI 20.6–30.6), significantly below the 45% performance goal (p<0.0001).
- No intraprocedural deaths, no hemodynamically significant LVOT obstruction, and no conversions to surgery occurred.
- Median follow-up was 1.4 years (IQR 1.0–2.1); mean STS-PROM for MVR was 6.6%, reflecting intermediate-to-high risk population.
Methodological Strengths
- Prospective multicountry multicentre pivotal design with prespecified performance goal
- Standardized device/procedure and systematic follow-up to 1 year
Limitations
- Single-arm design without randomized comparator limits causal inference
- Durability beyond 1–2 years and head-to-head comparisons with alternative therapies are unknown
Future Directions: Randomized comparisons versus TEER or optimized medical therapy in non-surgical MR subsets, longer-term durability and thrombogenicity surveillance, and refinement of anatomical selection criteria.
BACKGROUND: Patients with severe mitral regurgitation are frequently not candidates for surgery or transcatheter edge-to-edge repair (TEER). We aimed to evaluate 1-year outcomes of a novel percutaneous transseptal transcatheter mitral valve replacement (TMVR) system in patients unsuitable for surgery or TEER. METHODS: In this prospective, multicentre, single-arm, pivotal trial, adult patients (aged ≥18 years) with symptomatic moderate-to-severe or severe mitral regurgitation who were not suitable for surgery or TEER were recruited at 56 centres in six countries (the USA, Canada, the UK, the Netherlands, Israel, and Australia). Eligible patients were treated with TMVR using the SAPIEN M3 system (Edwards Lifesciences, Irvine, CA, USA). The primary endpoint was a non-hierarchical composite of all-cause mortality and heart failure rehospitalisation at 1 year in the as-treated population, compared with a prespecified performance goal of 45%. This trial is registered with ClinicalTrials.gov, NCT04153292, and is ongoing. FINDINGS: Between June 9, 2020, and Oct 10, 2023, 1171 patients were screened, of whom 299 were treated.
2. A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension.
An AI-driven pipeline digitizing a single RV pressure waveform image plus stroke volume accurately reconstructed RV pressure–volume loops and load-independent indices (Ees, Ea, Eed, Ees/Ea), with strong correlation to single-beat gold-standard estimates. Derived indices were prognostically informative: higher Ea (HR 2.09; 95% CI 1.04–4.20) and lower Ees/Ea (HR 0.27; 95% CI 0.08–0.87) predicted outcomes, and clustering revealed RV subphenotypes with distinct risk.
Impact: This methodological advance could democratize acquisition of RV load-independent metrics using routine catheterization data, enabling broader prognostication and phenotyping in pulmonary hypertension without specialized equipment.
Clinical Implications: Clinicians may leverage AI-estimated Ees, Ea, and Ees/Ea from routine traces to risk-stratify PH patients and guide therapy. Integration into cath lab workflow and EHR could enable practical RV–PA coupling assessment at scale.
Key Findings
- High correlation to single-beat gold standard: Ees R=0.96, Ea R=0.97, Eed R=0.87, Ees/Ea R=0.93 (with substantial CCC values).
- Prognostic value: higher Ea (HR 2.09; 95% CI 1.04–4.20) and lower Ees/Ea (HR 0.27; 95% CI 0.08–0.87) predicted clinical outcomes.
- Cluster analysis of single-beat indices identified two RV subphenotypes with distinct hemodynamics and outcome risks.
Methodological Strengths
- External validation across 3 centers with concordance to gold-standard single-beat methods
- Prognostic associations demonstrating clinical relevance beyond technical accuracy
Limitations
- Modest sample size (n=76) may limit generalizability and precision
- Performance may depend on quality of waveform images and accurate stroke volume input
Future Directions: Prospective multicenter deployment, integration into cath systems for real-time use, assessment of treatment responsiveness, and code/data sharing for reproducibility.
BACKGROUND: Load-independent indices of right ventricular (RV) dysfunction aid in the prognosis of patients with pulmonary hypertension (PH), but acquisition of these indices remains difficult. Simpler image-based tools could bring these metrics to everyday practice. OBJECTIVES: This study sought to develop a novel, artificial intelligence-based pipeline that estimates load-independent RV functional indices using a pressure-time waveform and stroke volume from clinical right-sided heart catheterization. METHODS: Clinical data and pressure-volume-time data were collected from 76 patients referred for right-sided heart catheterization for known or suspected PH from 3 centers. A computational pipeline was developed to determine the RV pressure-volume loop and extract load-independent RV indices using computer vision image processing and single-beat analysis. Agreement with gold standard single-beat analysis and prognostic value were evaluated. RESULTS: Strong concordance was observed between both methods for end-systolic elastance (Ees: R = 0.96; concordance correlation coefficient [CCC] = 0.58), effective arterial elastance (Ea: R = 0.97; CCC = 0.88), end-diastolic elastance (Eed: R = 0.87; CCC = 0.47), and Ees/Ea ratio (R = 0.93; CCC = 0.71) in both the validation and external cohorts.
3. Long-Term Durability of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valves: A Systematic Review and Meta-Analysis.
Across 22 studies (12,131 patients; median follow-up 7 years), overall moderate/severe SVD and BVF rates were 7% and 4%, respectively. BEV was associated with higher odds of SVD (OR 2.09; 95% CI 1.58–2.75) and BVF (OR 1.61; 95% CI 1.10–2.36) versus SEV, with no difference in all-cause mortality. Most implants were older-generation devices.
Impact: As TAVR expands to younger, lower-risk patients, long-term durability becomes pivotal. This synthesis suggests SEV may offer superior durability versus BEV over 5–8+ years, informing valve selection and follow-up strategies.
Clinical Implications: For patients with longer life expectancy, SEV may be preferred when feasible to mitigate SVD/BVF risk, though individualized decisions should consider anatomy, coronary access, and generation-specific performance. Long-term surveillance remains essential.
Key Findings
- Median follow-up 7 years (IQR 5–8.3); pooled moderate/severe SVD 7% and BVF 4%.
- BEV vs SEV: higher odds of SVD (OR 2.09; 95% CI 1.58–2.75; p<0.001) and BVF (OR 1.61; 95% CI 1.10–2.36; p=0.014).
- No significant difference in all-cause mortality between BEV and SEV groups.
Methodological Strengths
- Systematic review and meta-analysis with long-term (≥5 years) follow-up
- Large aggregated cohort (12,131 patients) with random-effects modeling
Limitations
- Predominant use of older-generation THVs (84.5%) may limit applicability to current devices
- Heterogeneity and observational nature of included studies; lack of patient-level data
Future Directions: Head-to-head long-term registries and RCTs with contemporary THVs, standardized SVD/BVF definitions, and evaluation of coronary access trade-offs over time.
BACKGROUND: Transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS) is increasingly performed in younger patients with long life expectancy. However, limited data exist on the durability of transcatheter heart valves (THVs). AIMS: The aim of the present work is to compare the long-term durability of balloon-expandable (BEV) and self-expanding (SEV) THVs after TAVR. METHODS: Electronic databases were searched up to May 2025 for studies reporting on the long-term durability of THVs in patients undergoing TAVR with a minimum follow-up of 5 years. Pooled odds ratios (ORs) with 95% confidence interval (CI) were used as summary statistics and were calculated using a random-effects model. Co-primary endpoints were moderate and severe structural valve deterioration (SVD) and the occurrence of all-cause bioprosthetic valve failure (BVF). All-cause death was the secondary endpoint. RESULTS: A total of 22 studies and 12,131 patients undergoing TAVR were included: 52.5% of patients (n = 6362) received BEV, 47.5% (n = 5769) SEV. An old-generation THV was used in 84.5% of cases.